PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
September 30, 2021Kardiologia PolskaOpen Access

Mavacamten — a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Current pharmacotherapy for HCM is not disease-specific and has suboptimal efficacy, often necessitating interventional treatment.

Does mavacamten improve peak oxygen consumption and NYHA class in adult patients with symptomatic obstructive hypertrophic cardiomyopathy?

Population

251 patients with HCM, LVOTO, and NYHA class II or III symptoms

Comparison

Mavacamten vs placebo

Design

Phase 3, randomized, double-blind, placebo-controlled, multicenter clinical trial

Authors

PPPiotr PyszRRRenata Rajtar-SalwaGSGrzegorz Smołka

Discussion

Loading...

Member takes

Overview

Supports mavacamten for symptomatic obstructive HCM; leaves open confirmation in broader populations.

Structured PICO

Does mavacamten improve peak oxygen consumption and NYHA class in adult patients with symptomatic obstructive hypertrophic cardiomyopathy?

P
Population
251 adult patients with obstructive hypertrophic cardiomyopathy (maximal LVOT gradient ≥50 mm Hg, LVEF ≥55%) and NYHA class II or III symptoms.
I
Intervention
Mavacamten oral once-daily (base dose 5 mg, up-titrated to maximum 15 mg) for 30 weeks.
C
Comparator
Matching placebo.
O
Outcome
Composite of either a ≥1.5 ml/kg/min increase in peak oxygen consumption (pVO2) and ≥1 NYHA class reduction or a ≥3.0 ml/kg/min pVO2 increase without NYHA class worsening.composite

Mavacamten, a first-in-class cardiac myosin inhibitor, significantly improves exercise capacity, LVOT obstruction, and symptoms in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Cite This Study

Pysz et al. (2021) studied this question.

synapsesocial.com/papers/6a832478f71f34e1aae8eb77https://doi.org/10.33963/kp.a2021.0064
View Full Paper
Ask AI
Bookmark
Share